Ipca Laboratories Ltd. News and Updates

Name: Latest research reports of Ipca Laboratories Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 4
Author: Prabhudas Lilladhar

Keep track of all breaking news on Ipca Laboratories Ltd. from all sources in a single place.

Ipca Laboratories Ltd.

14 Feb 2025

1407.05

0.35%

Ipca Labs Q3 Results Review India, Unichem Fuel Profitable Growth, Says Motilal Oswal, Raises Target Price

NDTV Profit

Ipca reported volume growth of 6-7% and the price hike was 5-6% YoY for the quarter, adds the brokerage.

Ipca Laboratories Ltd. is trading below its 50 day SMA of 1444.3

IPCA Laboratories share price jumps 7% after healthy Q3 results; details

Business Standard | 13 Feb 2025 1 more

Ipca Laboratories Ltd.

14 Feb 2025

1407.05

0.35%

IPCA LABORATORIES

Accumulate: Ipca Laboratories Ltd.

Prabhudas Lilladhar

Ipca Laboratories Ltd. is trading above its 30 day SMA of 1401.0

Ipca Laboratories Ltd.

13 Feb 2025

1407.05

0.35%

to see Rapid results content

Ipca Laboratories Ltd.

28 Jan 2025

1407.05

0.35%

Buy or sell stocks: Mehta Equities recommends short selling these 3 stocks in a volatile market

livemint

Buy or sell stocks: Riyank Arora of Mehta Equities recommends short selling Ipca Laboratories Ltd, Sun Pharmaceutical Industries Ltd, and H.G. Infra Engineering Ltd.

Ipca Laboratories Ltd. is trading above its 30 day SMA of 1401.0

Ipca Laboratories Ltd.

30 Dec 2024

1407.05

0.35%

Stock to buy today: IPCA Laboratories (1,630.55) BUY

Business Line

IPCA Laboratories share price can rise to 1,750

Ipca Laboratories Ltd. has an average target of 1815.00 from 3 brokers.

Ipca Laboratories Ltd.

27 Dec 2024

1407.05

0.35%

Scaling US operations/outpacing IPM to aid robust earnings growth

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Following a muted performance in the US over the past eight years due to compliance issues, IPCA is well-poised to revive its US business through new product launches, relaunches, stable pricing in its base business, and the integration of the Unichem business over the next 12-24M.

Ipca Laboratories Ltd. has an average target of 1815.00 from 3 brokers.

Ipca Laboratories Ltd.

18 Nov 2024

1407.05

0.35%

Ipca Labs Q2 Results Review - Operating Performance Inline: Dolat Capital

NDTV Profit

The brokerage believes that multiple triggers such as cost efficiencies and better scaleup are playing out in the Unichem portfolio.

Number of FII/FPI investors increased from 268 to 282 in Dec 2024 qtr.

Ipca Laboratories Ltd.

18 Nov 2024

1407.05

0.35%

IPCA LABORATORIES

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

Ipca Laboratories Ltd. is trading below its 50 day SMA of 1444.3

Ipca Laboratories Ltd.

15 Nov 2024

1407.05

0.35%

IPCA Laboratories Q2 Results 2024: Profit Rises by 58.2% YoY

livemint

IPCA Laboratories Q2 Results 2024 on 15 Nov, 2024: Revenue increased by 15.78% YoY & profit increased by 58.2% YoY, profit at 229.48 crore and revenue at 2354.9 crore.

Number of FII/FPI investors increased from 268 to 282 in Dec 2024 qtr.

Ipca Laboratories Ltd.

14 Nov 2024

1407.05

0.35%

Ipca Labs Q2 results: PAT rises 58% to Rs 229 cr, revenue at Rs 2,355 cr

Business Standard

Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period. Revenue from operations rose to Rs 2,355 crore for the second quarter of the current fiscal year as compared with Rs 2,034 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The company said its domestic formulations business revenue stood at Rs 940 crore for the quarter, up 11 per cent from Rs 845 crore a year earlier. Export of generics stood at Rs 286 crore in the July-September period as against Rs 264 crore, registering a year-on-year growth of 8 per cent. The company said its board has approved an interim dividend of Rs 21 per share of Re 1 each for 2024-25. Shares of the company on Thursday ended 2.02 per cent up at Rs 1,538.65 apiece on the BSE.